In the absence of biological insight or clinical data suggesting lower occupancies would be relevant for therapeutic areas other than TD [15] and chorea associated with Huntington’s disease [20], we recommend the 80–90% occupancy achieved by once daily valbenazine treatment serve as the gold standard for comparing to novel VMAT2 inhibitors in development. Here, SLC18A2 is linked to Huntington disease.